Presentation at AICon 2019

25 November 2019

Diaceutics PLC

("Diaceutics" or the "Company")

Presentation at AICon 2019

Diaceutics PLC (AIM: DXRX), the data analytics and implementation services company which services the global pharmaceutical industry, announces they will be presenting at the inaugural AICon, 2019. AICon will take place on Thursday, 28 November in The Europa Hotel, Belfast.

AICon is a world-class conference for professionals, developers, creatives, entrepreneurs and business leaders who have led on adopting artificial intelligence (AI) as a tool to provide better services, products and businesses. The event focuses on industry leaders currently working within the AI space from multiple industries. The topics of discussion will be primarily on breakthroughs and advantages of AI in current business processes, what the latest technologies are and how they are being applied in the relevant fields.

Wendy Moore, Knowledge & Insights Director and Scott Morrison, Data Science Director at Diaceutics will deliver a joint presentation on using AI/ML to improve patient pathways. They will discuss the challenges of (GDPR/HIPA) and how they effect the visibility of the pathway. As well as this, they will present the projects they are working on in the AI/ML field to give visibility into the patient pathway and the best actions a patient can take to get to an outcome.

A summary of the presentation content will be available on the Diaceutics website from 28 November.

Enquiries:

About Diaceutics

Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com